Heterocyclic FXR binding compounds

1. A compound of formula (I)

or an enantiomer, diastereomer, tautomer, or pharmaceutically acceptable salt thereof,

wherein

R 1 and R 2 are independently from each other selected from hydrogen, fluorine, cyano, nitro, azido, NR 5 R 6 , OR 5 , SR 5 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 6 cycloalkyl; or R 1 and R 2 are together ═S; or R 1 and R 2 may together form a 3-6-membered carbocyclic or heterocyclic ring which each can be unsaturated or saturated, wherein each alkyl, alkenyl, alkynyl, cycloalkyl group, carbocyclic or heterocyclic ring is unsubstituted or substituted with one to five substituents R 11 ;

R 5 and R 6 are independently from each other selected from hydrogen, C 1 -C 6 -alkyl and C 3 -C 6 -cycloalkyl; or R 5 and R 6 together may form a 3-6-membered saturated heterocyclic ring, wherein the alkyl, cycloalkyl and heterocyclic group is unsubstituted or substituted with one to five substituents R 11 ;

X is

R 3 is hydrogen, halogen, cyano, nitro, azido, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 6 cycloalkyl, heterocyclyl, aryl, heteroaryl, —NR 19 R 20 , NR 19 S(O) m R 20 , NR 19 C(O)OR 20 , NR 19 C(O)R 20 , NR 19 C(O)NR 19 R 20 , OR 19 , OC(O)R 19 , S(O) i R 19 , SO 2 NR 19 C(O)R 20 , S(O) m NR 19 R 20 , C(O)R 19 , C(O)OR 20 , C(O)NR 19 R 20 , C(NR 19 )NR 19 R 20 , wherein each alkyl, alkenyl, alkynyl, cycloalkyl heterocyclyl, aryl or heteroaryl is unsubstituted or substituted with one to five substituents R 11 ;

R 19 and R 20 are independently from each other selected from hydrogen, C 1 -C 6 -alkyl, C 2 -C 6 -alkenyl, C 2 -C 6 alkynyl and C 3 -C 6 -cycloalkyl, or R 19 and R 20 together may form a 3-7-membered heterocyclic or heteroaromatic ring, wherein the C 1 -C 6 -alkyl, C 2 -C 6 -alkenyl, C 3 -C 6 -cycloalkyl, heterocyclyl and heteroaryl group is unsubstituted or substituted with one to five substituents R 11 ;

R 4 is independently selected from hydrogen, halogen, cyano, nitro, azido, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 6 cycloalkyl, heterocyclyl, aryl, heteroaryl, NR 15 R 16 , NR 15 SO 2 R 16 , NR 15 C(O)OR 16 , NR 15 C(O)R 16 , NR 15 C(O)NR 15 R 16 , NR 15 C(NCN)NR 15 R 16 , OR 15 , OC(O)R 15 , S(O) i R 15 , SO 2 NR 15 C(O)R 16 , S(O) m NR 15 R 16 , SC(O)R 15 , C(O)R 15 , C(O)OR 15 , C(O)NR 15 R 16 , C(O)NHOR 15 , C(O)SR 15 and C(NR 15 )NR 15 R 16 , wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl or heteroaryl is unsubstituted or substituted with one to five substituents R 11 ;

and further two substituents R 4 can be taken together with the atom to which they attach to form a 4-7 membered carbocyclic, aryl, heteroaryl or heterocyclic ring, each of which is substituted or unsubstituted with one to five substituents R 11 ;

R 15 and R 16 are independently from each other selected from hydrogen, C 1 -C 6 -alkyl, C 2 -C 6 -alkenyl, C 2 -C 6 alkynyl and C 3 -C 6 -cycloalkyl; or R 15 and R 16 together may form a 3-7-membered heterocyclic or heteroaromatic ring, wherein the alkyl, alkenyl, cycloalkyl, heterocyclyl and heteroaryl groups are unsubstituted or substituted with one to five substituents R 11 ;

R 11 is independently selected from hydrogen, halogen, cyano, nitro, azido, ═O, ═S, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 6 cycloalkyl, heterocyclyl, aryl, heteroaryl, NR 12 R 13 , NR 12 S(O) m R 13 , NR 12 C(O)OR 13 , NR 12 C(O)R 13 , NR 12 C(O)NR 12 R 13 , NR 12 C(NCN)NR 12 R 13 , ═NOR 12 , —OR 12 , OC(O)R 12 , S(O) i R 12 , SO 2 NR 12 C(O)R 13 , S(O) m NR 12 R 13 , SC(O)R 12 , C(O)R 12 , C(O)OR 12 , C(O)SR 12 , C(O)NR 12 R 13 , C(O)NOR 12 , and C(NR 12 )NR 12 R 13 ;

R 12 and R 13 are independently from each other selected from hydrogen, C 1 -C 6 alkyl and C 3 -C 6 cycloalkyl, wherein each alkyl or cycloalkyl may be unsubstituted or substituted with one to five fluorines and/or one or two substituents selected from OH, OCH 3 , OCH 2 F, OCHF 2 , OCF 3 , ═O, SCF 3 , NH 2 , NHCH 3 and N(CH 3 ) 2 ; or R 12 and R 13 can be taken together with the atom to which they are attached to form a 4 to 6 membered carbocyclic, heteroaryl or heterocyclic ring, each of which may be unsubstituted or substituted with one to five fluorines and/or one or two substituents selected from OH, OCH 3 , —OCH 2 F, OCHF 2 , OCF 3 , ═O, SCF 3 , NH 2 , NHCH 3 and N(CH 3 ) 2 ;

Q is O;

T is —O—, —S—, —N(R 14 )—, CH 2 or CF 2 ;

R 14 is hydrogen, C 1 -C 3 -alkyl or C 3 -C 5 cycloalkyl, wherein each alkyl or cycloalkyl is unsubstituted or substituted with 1-5 fluorine atoms;

Y is selected from

R 8 is independently selected from hydrogen, halogen, cyano, nitro, azido, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 6 cycloalkyl, heterocyclyl, aryl, heteroaryl, NR 12 R 13 , NR 12 S(O) m R 13 , NR 12 C(O)OR 13 , NR 12 C(O)R 13 , NR 12 C(O)NR 12 R 13 , OR 12 , OC(O)R 12 , S(O) i R 12 , SO 2 NR 12 C(O)R 13 , S(O) m NR 12 R 13 , C(O)R 12 , C(O)OR 12 , C(O)NR 12 R 13 , and C(NR 12 )NR 12 R 13 , wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl or heteroaryl is unsubstituted or substituted with one to five substituents R 11 ;

Z is phenyl-A-R 9 , pyridyl-A-R 9 , pyrimidyl-A-R 9 or pyridazyl-A-R 9 , wherein phenyl, pyridyl, pyrimidyl or pyridazyl is unsubstituted or substituted with one to three groups selected from halogen, C 1 -C 4 alkyl, C 3 -C 5 cycloalkyl, C 2 -C 4 alkenyl, C 2 -C 4 alkynyl, cyano, OH, OCH 3 , OCH 2 F, OCHF 2 , OCF 3 , SCF 3 , NH 2 , NHCH 3 and N(CH 3 ) 2 ;

A is a bond, CH 2 , CHCH 3 , C(CH 3 ) 2 or CF 2 ;

R 9 is hydrogen, COOR 17 , CONR 17 R 18 , C(O)NHSO 2 R 17 , SO 2 NHC(O)R 17 , S(O) m R 17 , or tetrazole which is connected to A via the C-atom;

R 17 and R 18 are independently from each other selected from hydrogen, C 1 -C 6 -alkyl, C 2 -C 6 -alkenyl, C 2 -C 6 alkynyl and C 3 -C 6 -cycloalkyl; or R 17 and R 18 together may form a 3-7-membered heterocyclic or heteroaromatic ring, wherein the C 1 -C 6 -alkyl, C 2 -C 6 -alkenyl, C 3 -C 6 -cycloalkyl, heterocyclyl and heteroaryl groups are unsubstituted or substituted with one to five substituents R 11 ;

a is 0 or 1;

b is 1, 2 or 3;

c is 1 or 2;

i is 0, 1 or 2; and

m is 1 or 2.

2. The compound according to claim 1 , wherein

R 1 and R 2 are independently selected from hydrogen, fluorine and C 1-6 alkyl, wherein the alkyl group is unsubstituted or substituted with one to five substituents R 11 ; or R 1 and R 2 are together ═S.

3. The compound according to claim 1 , wherein

R 3 is hydrogen, C 1 -C 6 alkyl, NR 19 R 20 or C 3 -C 6 cycloalkyl, wherein each alkyl or cycloalkyl is unsubstituted or substituted with one to five substituents R 11 .

4. The compound according to claim 1 , wherein

R 4 is hydrogen, halogen, C 1-6 alkyl, O—C 1 -C 6 alkyl or CN, wherein each alkyl group is unsubstituted or substituted by one to five substituents R 11 .

5. The compound according to claim 1 , wherein

T is O, CH 2 or NR 14 .

6. The compound according to claim 1 , wherein

Y is selected from formula (Y 1 ), (Y 3 ) and (Y 5 ).

7. The compound according to claim 1 , wherein

R 8 is hydrogen, halogen, C 1 -C 6 -alkyl or O—C 1 -C 3 -alkyl, wherein each alkyl group is unsubstituted or substituted with one to five substituents R 11 .

8. The compound according to claim 1 , wherein

Z is phenyl-A-R 9 , wherein phenyl is unsubstituted or substituted with one to three groups selected from halogen, cyano, C 1-4 alkyl, OH, OCH 3 , OCH 2 F, OCHF 2 , OCF 3 , SCF 3 , NH 2 , NHCH 3 and N(CH 3 ) 2 .

9. The compound according to claim 1 , wherein

R 9 is COOR 17 or CONR 17 R 18 .

10. A medicament comprising the compound according to claim 1 .

11. A pharmaceutical composition comprising at least one compound according to claim 1 and at least one pharmaceutically acceptable excipient and/or carrier.

12. A method for the treatment of a disease or condition mediated by FXR comprising administering a composition comprising the compound of claim 1 .

13. The method according to claim 12 , wherein said disease or condition involves chronic intrahepatic or forms of extrahepatic cholestatic conditions, or liver fibrosis resulting from chronic cholestatic conditions or acute intraheptic cholestatic conditions.

14. The method according to claim 13 , wherein the chronic intraheptic or cholestatic conditions are primary biliary cirrhosis (PBC), primary sclerosing cholangitis (PSC), progressive familiar cholestasis (PFIC), alcohol-induced cirrhosis and associated cholestasis, or the liver fibrosis is estrogen or drug induced cholestasis.

15. The method according to claim 12 , wherein said disease or condition involves obstructive or chronic inflammatory disorders that arise out of improper bile composition.

16. The method according to claim 15 , wherein the obstructive or chronic inflammatory disorders are cholelithiasis (cholesterol gallstones).

17. The method according to claim 12 , wherein said disease or condition involves gastrointestinal conditions with a reduced uptake of dietary fat and fat-soluble dietary vitamins.

18. The method according to claim 12 , wherein said disease or condition is Inflammatory Bowel Diseases.

19. The method according to claim 18 , wherein the inflammatory bowel diseases are Crohn's disease or Colitis Ulcerosa.

20. The method according to claim 12 , wherein said disease or condition involves lipid and lipoprotein disorders.

21. The method according to claim 20 , wherein the lipid and lipoprotein disorders are hypercholesterolemia, hypertriglyceridemia, or atherosclerosis as a clinically manifest condition.

22. The method according to claim 12 , wherein said disease or condition is Type II Diabetes.

23. The method according to claim 12 , wherein said disease or condition involves clinical complications of Type I and Type II Diabetes.

24. The method according to claim 23 , wherein the clinical complications of Type I and Type II Diabetes are Diabetic Nephropathy, Diabetic Retinopathy, Diabetic Neuropathies or Peripheral Arterial Occlusive Disease (PAOD).

25. The method according to claim 12 , wherein said disease or condition is for conditions and diseases which result from chronic fatty and fibrotic degeneration of organs due to enforced lipid and specifically triglyceride accumulation and subsequent activation of profibrotic pathways.

26. The method according to claim 25 , wherein the conditions and diseases are Non-Alcoholic Steatohepatitis (NASH) and chronic cholestatic conditions in the liver, Glomerulosclerosis and Diabetic Nephropathy in the kidney, Macula Degeneration and Diabetic Retinopathy in the eye and Neurodegenerative diseases in the brain or Diabetic Neuropathies in the peripheral nervous system.

27. The method according to claim 12 , wherein said disease or condition is obesity and metabolic syndrome (combined conditions of dyslipidemia, diabetes and abnormally high body-mass index).

28. The method according to claim 12 , wherein said disease or condition is acute myocardial infarction, acute stroke, or thrombosis which occur as an endpoint of chronic obstructive atherosclerosis.

29. The method according to claim 12 , wherein said disease or condition is persistant infections by intracellular bacteria or parasitic protozoae.

30. The method according to claim 29 , wherein the bacteriyl or parasitic protozoae are selected from Mycobacterium spec. (Treatment of Tuberculosis or Lepra), Listeria monocytogenes (Treatment of Listeriosis), Leishmania spec. (Leishmaniosis), Trypanosoma spec. (Chagas Disease; Trypanosomiasis; Sleeping Sickness).

31. The method according to claim 12 , wherein said disease or condition is non-malignant hyperproliferative disorders.

32. The method according to claim 31 , wherein the non-malignant hyperproliferative disorders are increased neointima formation after balloon vessel dilatation and stent application due to increased proliferation of vascular smooth muscle cells (VSMCs) Bening Prostate Hyperplasia (BPH), or other forms of scar tissue formation and fibrotisation.

33. The method according to claim 12 , wherein said disease or condition involves malignant hyperproliferative disorders.

34. The method according to claim 33 , wherein the malignant hyperproliferative disorders are cancer.

35. The method according to claim 12 , wherein said disease or condition is liver steatosis and associated syndromes, cholestatic and fibrotic effects that are associated with alcohol-induced cirrhosis or with viral-borne forms of hepatitis.

36. The method according to claim 35 , wherein the liver steatosis associated syndrome is non-alcoholic steatohepatitis (“NASH”).

37. A method for preparing the compound of formula (I) according to claim 1 comprising the step of reacting a compound of formula (IXa) or of formula (IXb)

wherein

E N -H is OH, SH, NH 2 , N(R 14 )H, NH(CO)O-alkyl, NH(CO)O-aryl, NH(SO) 2 aryl, NH(SO) 2 alkyl, CH 3 or CF 2 H;

E L is halogen, OH, OC(O)alkyl, OC(O)aryl, O-aryl, O-pentafluorophenyl, O-sulfonylalkyl, O-sulfonylaryl, O-succinylimido, O-benzotriazolyl, nitro, azido, S-alkyl, SO 2 alkyl, SO 2 aryl, SC(O)alkyl, SC(O)aryl or cyano;

with a compound of formula (IVa) or (IVb), respectively

wherein

R 1 , R 2 and X are as defined previously and

E L and E N -H are as defined above;

in order to obtain a compound of formula (I)

wherein Z, Y, T, R 1 , R 2 and X are as defined previously.

38. The method according to claim 37 , comprising the further step of reacting a compound of formula (XII)

Z-L A   (XII)

wherein

Z is as defined previously and

L A is halogen, OH, B(OH) 2 , B(OMe) 2 , BF 3 − or 4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl;

with a compound of formula (XIII)

wherein

Y is as defined previously,

L B is halogen, OH, B(OH) 2 , B(OMe) 2 , BF 3 − or 4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl and

E is E L or E N -H;

in order to obtain a compound of formula (IX)

39. The method according to claim 37 , wherein

Z is as defined previously,

Y is Y 1 , Y 3 or Y 5 ,

T is O,

R 1 and R 2 are hydrogen and

a is 0.

40. The compound according to claim 1 , wherein Y is Y 1 or Y 3 .